Objective: Patients with major depressive disorder (MDD) often discontinue antidepressant therapy prematurely risking relapse, despite United Kingdom (UK) guidelines recommending therapy for up to at least six months after remission. More information is needed on the patterns of antidepressant discontinuation in UK primary care. Objectives of the study were to assess the patterns, incidence and predictors of therapy discontinuation among MDD patients initiating treatment with selective serotonin reuptake inhibitors (SSRIs). Methods: This was a retrospective cohort study using general practices registered with the General Practice Research Database (GPRD). 15,274 patients with MDD receiving a first ever prescription (index) for an SSRI between 2006-2008 were identified in GPRD. Discontinuation (including temporary gaps) and cessation of antidepressant therapy were examined over follow-up. Predictors of incidence of discontinuation in the six months after index were assessed. Results: Incidence of discontinuation of antidepressant therapy over follow-up was 80.05 per 100 person years (95% CI 78.94 -81.17). At six months after index 42% of patients had discontinued and 33% had ceased therapy altogether. Lower discontinuation of index SSRI therapy in the first six months after initiation was associated with higher age, higher body mass index (BMI), and comorbid irritable bowel syndrome. Higher discontinuation was associated with paroxetine or fluoxetine at index, and a more recent index calendar year. Conclusions: There is a significant risk of discontinuation of antidepressant therapy in the 6 months after initiation of treatment for MDD. This finding requires awareness by the general practitioner (GP) to ensure implementation of optimal treatment regimens, and minimization of therapy non-compliance among MDD patients.
INTRODUCTION
Approximately 13% of general practice attendees in the United Kingdom (UK) suffer major depressive disorder (MDD) [1] . Selective serotonin reuptake inhibitors (SSRIs) are recommended as a first-line treatment option due their relatively low cost, good efficacy and safety [2] . Therapy is recommended until depressive symptoms have been managed, and the patient is in remission. However, continuation of therapy is recommended for at least six months after remission to reduce risk of relapse [2] , and can be up to two years maintenance treatment if the patient has chronic depression, severe functional impairment, or is at risk of severe consequences such as suicide [2] . Premature discontinuation of antidepressant treatment is associated with a high risk of relapse and adverse consequences [3] including rapid re-onset of future depressive episodes, that can be more chronic and severe than if complete remission had been achieved, and moreover this risk is enhanced with untreated residual symptoms following a depressive episode [4, 5] . Hence, appropriate clinical management and reliable follow-up of patients suffering a depressive episode are important.
Discontinuation of antidepressant treatment can occur for several reasons [6] . Patients in remission from depression may discontinue therapy because they believe they can proceed with a non-depressed life without taking drugs. Patients may also discontinue due to an inadequate response to their initial treatment [7] , without implementation of appropriate alternative second-step treatment strategies [8] . Furthermore, patients may be noncompliant with their medication or discontinue because of adverse side effects [9, 10] . If we are to assess the potential unmet need in antidepressant treatment, it is per-tinent to examine patterns of therapy discontinuation and associated factors. The aim of this study was to assess incidence of discontinuation (including temporary treatment gaps) and cessation (discontinuation without subsequent therapy resumption) of antidepressant treatment among new initiators of SSRI treatment in UK primary care, and examine predictors of discontinuation in the six months after therapy initiation.
METHODS

Study Design and Data Source
This was a retrospective cohort study using data from the General Practice Research Database (GPRD) (www.cprd.com). GPRD is a large primary care database containing anonymised patient level medical and demographic information on approximately 8% of the UK population from 630 general practices. Containing approximately 11 million patients and 67 million patient years of data, the GPRD is a good resource for longitudinal epidemiological research, and has been widely used for studies on depression [11] [12] [13] [14] . The database contains information on diagnoses, symptoms, prescriptions, specialist referrals, test results, demographics, and administrative information.
Study Population
We extracted a cohort of adult patients who had received a first-time prescription for an SSRI between 01/06/2006 and 31/12/2008; this was the enrolment period and the date of first SSRI prescription was the index date. Patients were followed-up until 25/10/2010, where data were available.
Patients had to have registered with the practice at least 12 months before the index date to avoid collecting data from patients recently transferred into a practice who were likely to have historical diagnoses updated to their medical record [15] . Patients with prior prescriptions for antidepressants were excluded to ensure only new initiators of MDD therapy were included. In addition, inclusion was limited to patients with an index date after the practice became "up-to standard" (i.e. had good quality computerised data) (www.cprd.com), and those who were deemed "acceptable" according to GPRD's data quality criteria.
Our final study cohort comprised of patients with a specific Read code [16] for MDD or a positive score entry for MDD on a recommended [2] depression screening questionnaire (Patient Health Questionnaire (PHQ)-cut-off of 10 [17] , Hospital Anxiety and Depression Scale (HADS)-cut-off of 11 [18] , or the Beck Depression Inventory-II (BDI-II)-cut-off of 20 [19] ) in the period from six months before to three months after the index date. This window allowed inclusion of patients experiencing a time lag between diagnosis and treatment with SSRIs, and also for general practitioners (GPs) who entered a diagnosis after treatment had commenced. The PHQ is the most widely used measure and has been validated in UK primary care, showing high sensitivity (91.7%) and specificity (78.3%) for detection of MDD when compared with a gold-standard diagnostic clinical interview [20] .
Treatment Outcomes
The MDD treatment trajectory (using relevant drug code lists) was tracked among patients from the index date to the end of follow-up. Discontinuation was defined as discontinuation of an antidepressant prescription without receiving another within 60 days of exhausting the supply of the prior prescription. If there were any other adjacent (<60 days) therapy outcomes such as a drug switch, dose increase or adjunctive therapy then this was not classified as a discontinuation of the previous medication. Thus, discontinuation represented a gap in the treatment trajectory if the patient subsequently resumed MDD therapy, or was a cessation of therapy if no further antidepressant prescriptions were received up to the end of patient follow-up (to determine this accurately patients were required to have at least six months of follow-up after discontinuing with no prescriptions for antidepressants during that period).
Persistence on therapy was defined as remaining on antidepressants (not discontinuing as above) in the 12 months after index [21] , with allowable gaps of <60 days in treatment.
Covariates
Covariates included patient age at index, gender, and several baseline variables including depression severity, anxiety, alcohol and substance misuse, and chronic pain conditions (including irritable bowel syndrome, diabetic neuropathy, postherpetic neuropathy, trigeminal neuralgia, lumbar radiculopathy, cervical radiculopathy, complex regional pain syndrome, spinal cord injury, fibromyalgia, osteoarthritis, rheumatoid arthritis, migraine, chronic low back pain, ankylosing spondylitis, psoriatic arthropathy, and interstitial cystitis). These comorbidities were indentified using relevant Read code lists. We calculated the Charlson Comorbidity Index (CCI) [22] , an established measure of general disease burden that has been adapted for use with UK primary care databases [23] . These covariates were selected due to evidence of their association with depression and/or its treatment. For example, the concurrent treatment of pain conditions with non-steroidal anti-inflammatory drugs (NSAIDs) can reduce the efficiency of SSRIs [24] .
Statistics
Descriptive statistics, including frequency distributions, percentages, means (SD) and medians (10 th to 90 th percentiles) were used to describe baseline patient characteristics. Among patients with at least a year of follow-up data we calculated: 1) Persistence [21] at 12 months on the index SSRI, any SSRI, and any antidepressant; 2) Frequency of patients by duration of index medication; and 3) Median length of index therapy in the year after index.
Among all patients, Kaplan Meier methods were used to describe the cumulative failure pattern for: 1) Index SSRI therapy discontinuation; and 2) cessation of any antidepressant therapy. This was assessed from the index date up to the end of follow-up. Incidence of discontinuation of the index SSRI, any SSRI, and any antidepressant was calculated using total person-time at risk as a denominator.
The bivariate association of each covariate with incidence of discontinuation of the index SSRI in the six months after therapy initiation was tested individually using Poisson regression. Associations significant at the p = 0.10 level in the bivariate analysis were tested in an adjusted Poisson regression model to assess independent predictors of incidence of discontinuation of the index SSRI in the six months after therapy initiation. Wald tests aided modeling.
This study was reviewed and approved by the Independent Scientific Advisory Committee (protocol number 10_138).
RESULTS
94,932 eligible patients received a first-time SSRI prescription in the enrolment period. Of these, 2059 had a recent specific MDD Read code entry, and an additional 13,215 scored above the cut-off for MDD on the PHQ, HADs and/or BDI-II, resulting in a final study cohort of 15,274 patients. 13 antidepressant therapy. At three months after index 25% of patients had discontinued their index drug; at six months this was 42%, at 12 months 57%, at 24 months 64% and by 48 months 67% had discontinued their index medication. Twenty-two percent of patients had treat- ment cessation at three months after index, 33% at 6 months, 46% at 12 months, 59% at 24 months, and 69% at 48 months after index.
When considering the entire period of follow-up, overall incidence of discontinuation of the index SSRI was 51. 23 Table 2 shows a multivariable analysis of incidence of index therapy discontinuation in the first six months. Patients prescribed fluoxetine at index were 19% more likely (p ≤ 0.001) to discontinue compared with those starting on citalopram. Patients prescribed paroxetine at 
DISCUSSION
This study provides much needed UK data on discontinuation of antidepressant therapy among patients with MDD who were new initiators of treatment with SSRIs. Discontinuation was assessed as both temporary gaps in the depression treatment trajectory as well as true cessation of therapy, since gaps in treatment can indicate inadequate or under-treatment of depression. There are varying definitions of discontinuation of antidepressant therapy in the literature representing cessation (i.e. no further antidepressant prescription refills), and discontinuation defined using allowable gaps in prescriptions of <30 days [25, 26] , <90 days [27] , and <180 days [28] . In this study we opted for a 60 day allowable gap in antidepressant prescribing after which the patient was deemed to have discontinued.
Summary of Main Findings
Only a quarter of patients persisted on antidepressant medication up to at least one year after initiating MDD treatment, and 15% continued on their index SSRI medication at least up to this time. A high proportion of patients had only approximately a month's duration for their index therapy, suggesting many patients received a one-off antidepressant prescription. At six months after treatment initiation 42% of patients had discontinued their index drug, and 33% had cessation of therapy without subsequent resumption. Discontinuation of the index medication showed an increasing trend in more recent years. Higher discontinuation of the index treatment was associated with an index medication of fluoxetine or paroxetine compared with citalopram. Lower discontinuation of index medication was associated with older age, higher BMI, and IBS.
Study Cohort
Only 2059 and 13,215 of the 94,932 patients on SSRIs had a diagnostic Read code entry, and positive depresssion screening questionnaire score for MDD respectively. Since antidepressants are often used to treat several other disorders (e.g. Anxiety disorders, and eating disorders) this may account for some of the remaining patients who were not identified as MDD patients. The relatively small proportion of the final study cohort defined by a Read code entry for MDD likely reflects evidence of a trend in GPs recording symptom rather than diagnostic depression codes in the UK [29] . However, use of recommended [2] validated depression screening questionnaire scores allowed us to identify a population of MDD patients with high sensitivity and specificity [20] .
Comparison with Existing Literature
Other studies have also shown significant early discontinuation of first-time antidepressant therapy, with between 30% -53% of MDD patients discontinuing treatment during the six months after initiation [28, 30, 31] ; these percentages are comparable to those observed in our study. A similar extent of discontinuation (37% -56%) was observed among those treated for a new episode of depression, but who were not necessarily new initiators of therapy [32] [33] [34] .
The reasons for discontinuation are manifold. The most common reason for discontinuation given by patients in one study was "feeling better" [30] . Another study showed compliance with antidepressant treatment was twice as high among patients with high levels of polypharmacy compared with those with lower levels of polypharmacy [33] . Therefore, implementation of alternative strategies for inadequate responders to antidepressant therapy may enhance compliance and reduce the likelihood of discontinuation. Aikens et al. (2005) [35] found patient skepticism towards antidepressant therapy was a strong predictor of discontinuation. Medication side-effects, the most common of which are headache and nausea [9] , have also been shown to be associated with premature discontinuation of antidepressants [9, [31] [32] [33] [34] [35] .
Our multivariable analysis assessed factors associated with discontinuation of index therapy in the six months after therapy initiation. We chose this time window since it represented early discontinuers, and patients clearly falling short of the recommended six months of antidepressant maintenance treatment post remission [2] .
As in our study, other studies have also found older age to be associated with higher compliance [33] and longer-term [36] antidepressant therapy. Patient beliefs about medication are an important predictor of therapy adherence [37] . Another study by Aikens et al. (2008) [38] on patient beliefs about antidepressants found older patients were more likely to perceive a need for treatment and hence were less likely to discontinue therapy. Furthermore, patients with a relatively low comorbidity burden were likely to report an attitude of perceived harmfulness related to antidepressant therapy [38] , which may explain our findings of an association between presence of a comorbid condition (IBS) and a lower likelihood of discontinuation. Moreover, a higher comorbidity burden is likely to be associated with more contact with the GP, which may also increase the opportunity for treatment for depression.
Higher BMI was associated with a lower likelihood of discontinuation. This may be explained by the fact that patients remaining on SSRI treatment can be likely to suffer weight gain as a side effect [39] . However, there is also evidence that weight gain is associated with lower satisfaction and lower adherence to medication [40] and may indeed be a long-term predictor of discontinuation beyond the six-month window we examined.
The results also suggest an increasing trend in discontinuation of antidepressant therapy with more recent study enrolment years; this points to the need for implementation of better adherence strategies and improved patient-doctor communication. Another possible explanation could be a negative perception about antidepressant efficacy resulting from research showing limited difference between antidepressants and placebo [41, 42] .
Patients prescribed paroxetine or fluoxetine at index were more likely to discontinue in the first six months compared with patients prescribed citalopram. This may suggest relatively higher intolerability and adverse events associated with paroxetine and fluoxetine compared with citalopram [43, 44] , however there is little substantive evidence for differences in overall intolerability between SSRIs among non-select patients groups [45] . Furthermore, since patients were not randomly assigned to treatment, differences in unmeasured characteristics between patients prescribed citalopram, fluoxetine and paroxetine may explain the differing discontinuation rates.
Study Strengths and Limitations
1) It is possible that MDD patients without a diagnostic Read code entry or a depression screening questionnaire score entry indicating MDD were missed; 2) We were not able to identify possible antidepressant prescriptions received from mental health specialists. However, we would expect a relatively small proportion of patients, mainly those who were treatment-resistant, to have been likely to be under the sole care of a specialist rather than their GP;
3) Reasons for discontinuation were not available in GPRD. Future studies using GPRD may utilize additional free text information which may provide such information; 4) GPRD contains information on drugs prescribed and does not verify whether the medication was dispensed or taken by the patient;
5) The results cannot be generalized to MDD patients who are not new initiators of antidepressant therapy, since their treatment course may differ from those on first time antidepressant therapy;
6) It was beyond the scope of the study to examine psychological therapies; future studies may consider this to determine whether patients who discontinue pharmacological treatment early are likely to be receiving psychological therapies instead.
CONCLUSIONS AND IMPLICATIONS
There is a significant risk of discontinuation of antide-pressant therapy in the six months after initiation of treatment for MDD. This requires awareness by the clinician both in terms of ensuring an optimal treatment regimen is implemented, and also in helping minimize non-compliance from MDD patients in persisting with their prescribed therapy [31] . GPs should monitor their MDD patients initiating pharmacotherapy for presence of depressive symptoms, and adhere to recommended guidelines by continuing antidepressant therapy for up to at least six months after remission to avoid risk of relapse of depression. Moreover, the importance of continuing treatment even if their depressed mood has improved should be appropriately communicated to the patient. GPs should aim to minimise discontinuation and optimise adherence to antidepressant therapy by active follow-up of patients suffering potential inadequate or non-response to pharmacotherapy, and those experiencing adverse side effects from their antidepressant medication. If such problems are identified, GPs should implement alternative treatment strategies such as a dose increase, therapy switch, augmentation or referral to a specialist.
